There is a lot of talk about a drug that seems particularly effective in combating one of the main health challenges of our time.
L’pharmaceutical industry is constantly looking for innovative products that meet consumer needs and solve common health problems. This incessant research led to the birth of revolutionary drugs that they promise significant improvements in quality of life. Recently, a new drug has attracted attention for its enormous success and its close connection to nutrition, arousing the interest of both health professionals and the food industry.
This drug, which is enjoying incredible success, has generated a wide debate regarding its potential and its effects. As often happens with innovations of this magnitude, it is essential to carefully analyze all aspects related to its use, including the benefits and potential risks, to provide complete and correct information to the public.
Developed by Denmark’s Novo Nordisk, Wegovy was approved by the U.S. Food and Drug Administration (FDA) in June 2021 as a weight loss treatment. Recently, it has also the Chinese authorities have given the green light for its usefurther expanding the market for this innovative drug.
The drug everyone is talking about
We are talking about the Wegsa weekly injectable medicine prescribed for Helping adults with obesity or excess weight associated with weight-related medical problems. The active ingredient is semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, which works by reducing hunger, increasing satiety, and delaying gastric emptying.
This leads to a significant weight loss when combined with a low-calorie diet and increased physical activity. The drug has been the subject of clinical studies that have demonstrated its effectiveness. In a study sponsored by Novo Nordisk, participants who took Wegovy for 68 weeks they lost an average of 16% of their body weightcompared to 5.7% of participants who took a placebo.
However, as with all medications, there are some Contraindications and possible side effects. Wegovy should not be taken by people with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2), nor by those who are allergic to semaglutide.
Furthermore, women who are pregnant or planning to become pregnant within two months they should avoid taking Wegovy. Common side effects include nausea, diarrhea, constipation, and headache, but they are generally short-lived.
The approval of this drug by global health authorities, including the recent approval in China, represents an important step in the fight against obesity. With the number of obese adults in China expected to reach 540 million by 2030, the availability of an effective treatment like Wegovy could make a difference for many people.
Disable push notifications
